[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2298766T3 - Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny - Google Patents

Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny

Info

Publication number
PL2298766T3
PL2298766T3 PL10182072T PL10182072T PL2298766T3 PL 2298766 T3 PL2298766 T3 PL 2298766T3 PL 10182072 T PL10182072 T PL 10182072T PL 10182072 T PL10182072 T PL 10182072T PL 2298766 T3 PL2298766 T3 PL 2298766T3
Authority
PL
Poland
Prior art keywords
comrpising
pharmaceutical formulations
pyridine derivative
substituted pyridine
derivative
Prior art date
Application number
PL10182072T
Other languages
English (en)
Inventor
Christian Wenzel Tornøe
Nikolay Khanzhin
Mario Rottländer
William Patrick Watson
Daniel Rodriguez Greve
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PL2298766T3 publication Critical patent/PL2298766T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10182072T 2005-03-03 2006-03-02 Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny PL2298766T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65842805P 2005-03-03 2005-03-03
DKPA200500321 2005-03-03
EP10182072.8A EP2298766B1 (en) 2005-03-03 2006-03-02 Pharmaceutical formulations comrpising a substituted pyridine derivative
EP06706094A EP1861394A1 (en) 2005-03-03 2006-03-02 Substituted pyridine derivatives

Publications (1)

Publication Number Publication Date
PL2298766T3 true PL2298766T3 (pl) 2014-09-30

Family

ID=36544250

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10182072T PL2298766T3 (pl) 2005-03-03 2006-03-02 Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny

Country Status (11)

Country Link
US (2) US7812020B2 (pl)
EP (2) EP2298766B1 (pl)
JP (2) JP5237643B2 (pl)
AU (1) AU2006220130B2 (pl)
CA (1) CA2599890C (pl)
CY (1) CY1114561T1 (pl)
HR (1) HRP20130973T1 (pl)
MX (1) MX2007010547A (pl)
NO (1) NO20074959L (pl)
PL (1) PL2298766T3 (pl)
WO (1) WO2006092143A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
US20070078177A1 (en) * 2005-09-30 2007-04-05 Washington University In St. Louis Methods and compositions for treating non age related hearing impairment in a subject
EA017915B1 (ru) 2006-02-07 2013-04-30 Х. Лундбекк А/С Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
CN101563085A (zh) 2006-08-23 2009-10-21 威朗国际制药公司 作为钾通道调节剂的4-(n-氮杂环烷基)酰苯胺的衍生物
ATE538084T1 (de) 2006-11-28 2012-01-15 Valeant Pharmaceuticals Int Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
WO2009015667A1 (en) * 2007-08-01 2009-02-05 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010094645A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094644A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010097379A1 (en) 2009-02-24 2010-09-02 Neurosearch A/S Substituted pyrimidin derivatives and their medical use
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
US20120232058A1 (en) 2009-09-07 2012-09-13 Neurosearch A/S Substituted pyridine derivatives and their medical use
EP2475656A1 (en) 2009-09-07 2012-07-18 NeuroSearch A/S 2, 3, 6 -triamino substituted pyridines as kv7 (kcnq) channel modulators
CN103189357B (zh) 2010-08-27 2015-11-25 格吕伦塔尔有限公司 作为kcnq2/3调节剂的取代的2-氧代-和2-硫代-二氢喹啉-3-甲酰胺
CN103068804B (zh) 2010-08-27 2015-08-19 格吕伦塔尔有限公司 作为kcnq2/3调节剂的取代的2-氧基-喹啉-3-甲酰胺
MX2013000748A (es) 2010-08-27 2013-03-05 Gruenenthal Gmbh 2-amino-quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
JP5976649B2 (ja) 2010-09-01 2016-08-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換１−オキソ−ジヒドロイソキノリン−３−カルボキサミド
KR101820645B1 (ko) * 2010-10-20 2018-01-22 그뤼넨탈 게엠베하 Ｋｃｎｑ２／３ 조절제로서의 치환된 ６­아미노­니코틴아미드
AU2015201122B2 (en) * 2010-10-20 2016-02-25 Grunenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
US9168259B2 (en) 2010-10-20 2015-10-27 Grünenthal GmbH Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
WO2013004249A1 (en) 2011-07-05 2013-01-10 Concit Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
JP2015516969A (ja) 2012-04-18 2015-06-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換４−アミノベンズアミド
PL3160464T3 (pl) 2014-06-26 2018-12-31 Contera Pharma Aps 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
US11440912B2 (en) * 2017-10-27 2022-09-13 Fresenius Kabi Oncology Ltd Process for the preparation of ribociclib and its salts

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5981525A (en) * 1995-01-10 1999-11-09 Smithkline Beecham Corporation Indole derivatives useful in the treatment of osteoporosis
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
EP1033366A3 (en) * 1999-02-18 2000-12-27 Pfizer Products Inc. Amide derivatives useful as Neuropeptide Y (NPY) antagonists
DE60037321T4 (de) 1999-08-04 2010-01-07 Icagen, Inc. Benzanilide als öffner des kaliumkanals
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
AU2001263486A1 (en) 2000-05-26 2001-12-11 Bristol-Myers Squibb Company Human KCNQ5 potassium channel, methods and compositions thereof
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
JP2003206230A (ja) * 2002-01-10 2003-07-22 Yamanouchi Pharmaceut Co Ltd シアノヘテロ環誘導体又はその塩
SG157231A1 (en) * 2003-03-21 2009-12-29 Lundbeck & Co As H Substituted p-diaminobenzene derivatives
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives

Also Published As

Publication number Publication date
CY1114561T1 (el) 2016-10-05
NO20074959L (no) 2007-10-02
US20080318953A1 (en) 2008-12-25
JP5705249B2 (ja) 2015-04-22
MX2007010547A (es) 2007-10-03
EP2298766B1 (en) 2013-09-18
CA2599890A1 (en) 2006-09-08
JP2008531609A (ja) 2008-08-14
AU2006220130B2 (en) 2011-07-28
JP2013136613A (ja) 2013-07-11
WO2006092143A1 (en) 2006-09-08
EP1861394A1 (en) 2007-12-05
CA2599890C (en) 2011-05-03
AU2006220130A1 (en) 2006-09-08
HRP20130973T1 (hr) 2013-11-22
EP2298766A1 (en) 2011-03-23
US20110003811A1 (en) 2011-01-06
US7812020B2 (en) 2010-10-12
US8299071B2 (en) 2012-10-30
JP5237643B2 (ja) 2013-07-17

Similar Documents

Publication Publication Date Title
PL2298766T3 (pl) Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny
IL186521A0 (en) Nanoparticle-active ingredient conjugates
EP1912671A4 (en) BETA-glucuronide LINKER ARZNEIKONJUGATE
EP1741703A4 (en) PYRIDONE DERIVATIVE
HK1107347A1 (en) 3-arylamino pyridine derivatives 3-
IL180430A0 (en) Pyridine derivatives
HK1203351A1 (en) Pharmaceutical composition comprising a glucopyranosyl substituted benzene derivative
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
IL177566A0 (en) Pharmaceutical formulations
IL189139A0 (en) Trazodone composition for once a day administration
IL180331A0 (en) 3-carbamoyl - 2 - pyridone derivative
ZA200802947B (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
IL182703A0 (en) Pharmaceutical compositions comprising a camtothecin derivative
IL193774A0 (en) Pharmaceutical compositions containing a 3,5-seco-4-norcholestane derivative
EP1820797A4 (en) SUBSTITUTED PYRIDONE DERIVATIVE
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
EP1718335A4 (en) CONJUGATES OF DRUGS
GB0423800D0 (en) New pharmaceutical formulations
IL198160A0 (en) Pharmaceutical formulations
SI2298766T1 (sl) Farmacevtske formulacije, ki vsebujejo substituiran derivat piridina
HK1092734A1 (en) Oral formulation for twice-daily administration
GB0406048D0 (en) Drug formulations
EP1864664A4 (en) PHARMACEUTICAL PREPARATION
GB0612556D0 (en) Topical pharmaceutical formulations
GB0522473D0 (en) A pharmaceutical formulation